SLC5A2 and type 2 diabetes mellitus: Therefore, we utilized the network pharmacology analysis system to determine the targets of SGLT2 inhibitors on the cardiorenal protection of T2DM and identify the biological pathways involved to provide directions for in-depth investigation of SGLT2 inhibitors.